Tech Transfer eNews Blog
University-Industry Engagement Advisor

U of Copenhagen start-up teams with Novo Nordisk to develop treatments for obesity

By Jesse Schwartz
Published: November 7th, 2018

University of Copenhagen start-up Embark Biotech ApS and pharmaceutical giant Novo Nordisk have entered into a research collaboration to develop novel treatments for obesity and its associated metabolic diseases.

The goal of the partnership is to create drug candidates that help people with obesity lose weight by burning off excess energy instead of storing it as fat. The research platform builds on discoveries around receptors that stimulate energy expenditure without triggering the sympathetic nervous system, potentially creating an energy expenditure drug that would help obese patients lose weight.

 As part of the collaboration, Embark will receive research support from Novo Nordisk, which in turn will have an option to license exclusive worldwide rights to develop and commercialize products discovered in the collaboration.

“We see the research collaboration with Novo Nordisk, a global leader within obesity care, as the optimal way of developing the technology to ultimately benefit the patients,” says Thue W. Schwartz, professor at the University of Copenhagen and co-founder of Embark.

“There is a huge unmet medical need for treatment of obesity,” says Marcus Schindler, senior vice president of global drug discovery at Novo Nordisk. “While more than 650 million people are currently living with obesity, it is rarely acknowledged, diagnosed or treated as a serious chronic and complex disease. We believe that Novo Nordisk and Embark together have both the capability and capacity to explore this new mechanism of action.”

Source: PipelineReview

Posted under: Tech Transfer e-News

Twitter Facebook Linkedin Pinterest Email

No Comments so far ↓

There are no comments yet...Kick things off by filling out the form below.

Leave a Comment